X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs DR. REDDYS LAB - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA DR. REDDYS LAB GLENMARK PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 10.8 20.1 53.8% View Chart
P/BV x 1.9 3.0 64.4% View Chart
Dividend Yield % 0.5 0.8 69.0%  

Financials

 GLENMARK PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
DR. REDDYS LAB
Mar-19
GLENMARK PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs9302,875 32.3%   
Low Rs5171,888 27.4%   
Sales per share (Unadj.) Rs322.6930.2 34.7%  
Earnings per share (Unadj.) Rs28.5117.4 24.3%  
Cash flow per share (Unadj.) Rs39.2185.8 21.1%  
Dividends per share (Unadj.) Rs2.0020.00 10.0%  
Dividend yield (eoy) %0.30.8 32.9%  
Book value per share (Unadj.) Rs183.0844.4 21.7%  
Shares outstanding (eoy) m282.17166.07 169.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.22.6 87.6%   
Avg P/E ratio x25.420.3 125.2%  
P/CF ratio (eoy) x18.512.8 144.0%  
Price / Book Value ratio x4.02.8 140.2%  
Dividend payout %7.017.0 41.2%   
Avg Mkt Cap Rs m204,206395,496 51.6%   
No. of employees `00013.722.0 62.4%   
Total wages/salary Rs m18,71833,562 55.8%   
Avg. sales/employee Rs Th6,636.87,032.8 94.4%   
Avg. wages/employee Rs Th1,364.71,527.9 89.3%   
Avg. net profit/employee Rs Th586.1887.7 66.0%   
INCOME DATA
Net Sales Rs m91,031154,482 58.9%  
Other income Rs m9143,375 27.1%   
Total revenues Rs m91,945157,857 58.2%   
Gross profit Rs m16,15431,782 50.8%  
Depreciation Rs m3,01911,348 26.6%   
Interest Rs m2,856889 321.2%   
Profit before tax Rs m11,19322,920 48.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1553,858 81.8%   
Profit after tax Rs m8,03919,500 41.2%  
Gross profit margin %17.720.6 86.3%  
Effective tax rate %28.216.8 167.4%   
Net profit margin %8.812.6 70.0%  
BALANCE SHEET DATA
Current assets Rs m69,887111,101 62.9%   
Current liabilities Rs m32,87958,973 55.8%   
Net working cap to sales %40.733.7 120.5%  
Current ratio x2.11.9 112.8%  
Inventory Days Days8179 102.6%  
Debtors Days Days9394 99.3%  
Net fixed assets Rs m28,892101,245 28.5%   
Share capital Rs m282830 34.0%   
"Free" reserves Rs m51,353139,406 36.8%   
Net worth Rs m51,635140,236 36.8%   
Long term debt Rs m41,41822,000 188.3%   
Total assets Rs m125,954224,656 56.1%  
Interest coverage x4.926.8 18.4%   
Debt to equity ratio x0.80.2 511.3%  
Sales to assets ratio x0.70.7 105.1%   
Return on assets %8.69.1 95.3%  
Return on equity %15.613.9 112.0%  
Return on capital %15.114.9 101.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31788,673 41.0%   
Fx outflow Rs m9,72019,104 50.9%   
Net fx Rs m26,59869,569 38.2%   
CASH FLOW
From Operations Rs m16,48128,704 57.4%  
From Investments Rs m-10,133-7,727 131.1%  
From Financial Activity Rs m-4,685-21,326 22.0%  
Net Cashflow Rs m1,770-314 -563.7%  

Share Holding

Indian Promoters % 48.3 25.5 189.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 5.4 127.8%  
FIIs % 34.4 35.3 97.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 10.5 15.3 68.6%  
Shareholders   56,727 75,885 74.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SANOFI INDIA  ABBOTT INDIA  PLETHICO PHARMA  CIPLA  TORRENT PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 23, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS